13
Jul
2023

Recursion’s Big Day, FDA OKs OTC Birth Control & a Midsummer IPO

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Danaher Wins Over Abcam, Sage Cuts, & FTC Ceases Fire With Amgen
Rapport’s $150M Advance, Regeneron’s New COVID Challenge, and a Traverse for the Ages
Gilead Bets on Multi-Functionals, Taysha Revived & Google Spotlights Illumina Rival
Sage Gets FDA OK for PPD, Wegovy’s Home Run, & Illumina’s Gloomy Quarter